Jan C. Grutters
Jan C. Grutters
Professor of Interstitial Lung Diseases
Verified email at antoniusziekenhuis.nl
TitleCited byYear
Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis
L Richeldi, RM Du Bois, G Raghu, A Azuma, KK Brown, U Costabel, ...
New England Journal of Medicine 370 (22), 2071-2082, 2014
21082014
Dexamethasone and length of hospital stay in patients with community-acquired pneumonia: a randomised, double-blind, placebo-controlled trial
SCA Meijvis, H Hardeman, HHF Remmelts, R Heijligenberg, GT Rijkers, ...
The Lancet 377 (9782), 2023-2030, 2011
2952011
Surfactant protein C mutations are the basis of a significant portion of adult familial pulmonary fibrosis in a dutch cohort
CHM van Moorsel, MFM van Oosterhout, NP Barlo, PA de Jong, ...
American journal of respiratory and critical care medicine 182 (11), 1419-1425, 2010
2142010
The WASOG Sarcoidosis Organ Assessment Instrument: an update of a previous clinical tool
MA Judson, U Costabel, M Drent, A Wells, L Maier, L Koth, H Shigemitsu, ...
Sarcoidosis Vasculitis and diffuse Lung Diseases 31 (1), 19-27, 2014
2012014
HLA-DQB1* 0201: a marker for good prognosis in British and Dutch patients with sarcoidosis
H Sato, JC Grutters, P Pantelidis, AN Mizzon, T Ahmad, AJ van Houte, ...
American journal of respiratory cell and molecular biology 27 (4), 406-412, 2002
1832002
Corticosteroid treatment in sarcoidosis
JC Grutters, JMM Van den Bosch
European Respiratory Journal 28 (3), 627-636, 2006
1752006
Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: a case-cohort study
SLF Walsh, AU Wells, SR Desai, V Poletti, S Piciucchi, A Dubini, H Nunes, ...
The lancet Respiratory medicine 4 (7), 557-565, 2016
1722016
Serum soluble interleukin-2 receptor measurement in patients with sarcoidosis: a clinical evaluation
JC Grutters, JM Fellrath, L Mulder, R Janssen, JMM van den Bosch, ...
Chest 124 (1), 186-195, 2003
1622003
Increased frequency of the uncommon tumor necrosis factor− 857T allele in British and Dutch patients with sarcoidosis
JC Grutters, H Sato, P Pantelidis, AL Lagan, DS McGrath, JWJ Lammers, ...
American journal of respiratory and critical care medicine 165 (8), 1119-1124, 2002
1622002
Oxidized BAL fluid proteins in patients with interstitial lung diseases
AG Lenz, U Costabel, KL Maier
European Respiratory Journal 9 (2), 307-312, 1996
152*1996
CC chemokine receptor 2 and sarcoidosis: association with Lofgren's syndrome
P Spagnolo, EA Renzoni, AU Wells, H Sato, JC Grutters, P Sestini, ...
American journal of respiratory and critical care medicine 168 (10), 1162-1166, 2003
1432003
Methotrexate vs azathioprine in second-line therapy of sarcoidosis
ADM Vorselaars, WA Wuyts, VMM Vorselaars, P Zanen, VHM Deneer, ...
Chest 144 (3), 805-812, 2013
1342013
Genetics of fibrosing lung diseases
JC Grutters, RM Du Bois
European Respiratory Journal 25 (5), 915-927, 2005
1252005
Combination therapy: the future of management for idiopathic pulmonary fibrosis?
WA Wuyts, KM Antoniou, K Borensztajn, U Costabel, V Cottin, B Crestani, ...
The lancet Respiratory medicine 2 (11), 933-942, 2014
1122014
Systemic cytokine response in patients with community-acquired pneumonia
H Endeman, SCA Meijvis, GT Rijkers, H van Velzen–Blad, ...
European Respiratory Journal 37 (6), 1431-1438, 2011
1012011
18F-FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab
RG Keijsers, JF Verzijlbergen, DM Van Diepen, JM Van den Bosch, ...
Sarcoidosis Vasc Diffuse Lung Dis 25 (2), 143-9, 2008
962008
Serum and BALF YKL-40 levels are predictors of survival in idiopathic pulmonary fibrosis
NM Korthagen, CHM van Moorsel, NP Barlo, HJT Ruven, A Kruit, M Heron, ...
Respiratory medicine 105 (1), 106-113, 2011
932011
Human neutrophils switch to an activated phenotype after homing to the lung irrespective of inflammatory disease
E Fortunati, KM Kazemier, JC Grutters, L Koenderman, ...
Clinical & Experimental Immunology 155 (3), 559-566, 2009
922009
Sarcoidosis HLA class II genotyping distinguishes differences of clinical phenotype across ethnic groups
H Sato, FA Woodhead, T Ahmad, JC Grutters, P Spagnolo, ...
Human molecular genetics 19 (20), 4100-4111, 2010
892010
Defining the clinical outcome status (COS) in sarcoidosis: results of WASOG Task Force
RP Baughman, S Nagai, M Balter, U Costabel, M Drent, R Du Bois, ...
Sarcoidosis vasc diffuse lung dis 28 (1), 56-64, 2011
882011
The system can't perform the operation now. Try again later.
Articles 1–20